Congress Materials – American College of Gastroenterology (ACG 2025)
2025 American College of Gastroenterology | Oct 24-2 | Phoenix, AZ
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Comparison of serum IL-22 and tissue molecular changes between guselkumab subcutaneous and intravenous induction in moderately to severely active Crohn’s disease: post-hoc analysis of the GRAVITI and GALAXI studies
Sohn, Richards, Patel, Hart, Sisk, Olurinde, Terry, McRae, Reinisch, Steinwurz, Panaccione, D’Haens, Branigan
This document will be available on October 26th 2025
Effect of guselkumab subcutaneous induction and maintenance on symptoms of moderately to severely active ulcerative colitis as measured by the UC-PRO/SS: results from the phase 3 ASTRO study
Danese, Peyrin-Biroulet, Long, Germinaro, Baker, Alvarez, Kavalam, Han, Jorgens, Jiang, Zhang, Hisamatsu, Rubin, Allegretti
This document will be available on October 2th 2025
Effects of subcutaneous guselkumab induction and maintenance on histologic outcomes in patients with moderately to severely active Crohn’s disease in GRAVITI, a Phase 3 double-blind, placebo-controlled, treat-through study
D’Haens, Hart, Panaccione, Steinwurz, Cao, Olurinde, Salese, Branigan, van Duijnhoven, Terry, Danese, Hisamatsu, Sands
This document will be available on October 26th 2025
Efficacy and safety of icotrokinra, a targeted oral peptide that selectively blocks IL-23 receptor activation, in ulcerative colitis: results from week 28 of ANTHEM-UC, a phase 2b dose-ranging trial
Jairath, Siegmund, Surace, Erondu, Chen, Chachu, Louis, Matsuoka, Limdi, Arthur, Houck, Frustaci, Zhan, Rydzewska, Loftus, Abreu
This document will be available on October 26th 2025
Efficacy and safety of subcutaneous guselkumab induction and maintenance therapy in patients with ulcerative colitis: results through week 48 from the phase 3 ASTRO study
Allegretti, Peyrin-Biroulet, Long, Germinaro, Baker, Kavalam, Alvarez, Hertzog, Jorgens, Zhang, Jiang, Hisamatsu, Rubin, Danese
This document will be available on October 26th 2025
Efficacy and safety of subcutaneous guselkumab rescue therapy in patients with moderately to severely active Crohn’s disease and inadequate response to ustekinumab: results from GALAXI 1, 2, & 3 long-term extension
Afzali, Wolf, Leong,Van Rampelbergh, Van Duijnhoven, Busse, Hisamatsu, Panés
This document will be available on October 26th 2025
Efficacy by baseline disease characteristics of intravenous and subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: results at week 12 from the phase 3 GALAXI and GRAVITI studies
Sands, Hisamatsu, Afzali, Terry, Olurinde, Van Rampelbergh, Yee, van Duijnhoven, Hart, Danese, Panaccione
This document will be available on October 26th 2025
Efficacy of guselkumab in moderately to severely active ulcerative colitis by extent of disease and inflammatory burden: subgroup analysis of the Phase 3 QUASAR maintenance study
Allegretti, Hisamatsu, Bressler, Peyrin-Biroulet, Germinaro, Yarandi, Shipitofsky, Miao, Sands, Rubin, Dignass
This document will be available on October 26th 2025
Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn’s disease in the GALAXI Phase 3 Studies
Afzali, Hisamatsu, Rubin, Terry, Van Rampelbergh, Yee, Yi Wan, Yang, Reinisch, Sands, Danese, Panaccione
This document will be available on October 26th 2025
Guselkumab pharmacokinetics and exposure-response relationships are consistent following intravenous versus subcutaneous induction in participants with Crohn’s disease
D’Haens, Adedokun, Yang, Sands, Danese, Terry, Olurinde, Van Rampelbergh, Vetter, Hisamatsu, Panaccione
This document will be available on October 26th 2025
Impact of subcutaneous guselkumab induction therapy on molecular inflammation in patients with ulcerative colitis: results from the phase 3 ASTRO study
Venkat, Sridhar, Shaikh, Sohn, Liu, Sisk, McRae, Alvarez, Baker, Germinaro, Allegretti, Long, Rubin, Peyrin-Biroulet, Hart, Branigan
This document will be available on October 26th 2025
Induction efficacy of subcutaneous guselkumab vs advanced therapies in moderately-to-severely active Crohn’s disease: a Bayesian network meta-analysis
Sanon, Neviere, Naessens, Friedrich, Chopard-Lallier, Yang, Hoops, Kachroo, Papadimitropoulou
This document will be available on October 26th 2025
Inhibition of structural damage progression with guselkumab in participants with active psoriatic arthritis: results through week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study
Mease, Ritchlin, Coates, Kollmeier, Zhou, Jiang, Bensley, Im, Batra, Chakravarty, Rahman, Van Der Heijde
This document will be available on October 26th 2025
Investigating unmet needs among advanced therapy-naïve patients with Crohn’s disease treated with ustekinumab or risankizumab
Caldera, Zhdanava, Kachroo, Shah, Diaz, Jiang, Kerner, Pilon, Seminerio
This document will be available on October 26th 2025
Investigating unmet needs among advanced therapy-naïve patients with Crohn’s disease treated with ustekinumab or upadacitinib
Caldera, Zhdanava, Kachroo, Shah, Diaz, Jiang, Kerner, Pilon, Seminerio
This document will be available on October 26th 2025
Long-term efficacy and safety of guselkumab through week 96 after intravenous or subcutaneous induction in participants with Crohn’s disease: findings from the long-term extension periods of the phase 3 GALAXI 2, GALAXI 3, and GRAVITI Studies
D'Haens, Rubin, Afzali, Hart, Hisamatsu, Terry, Olurinde, Van Rampelbergh, Yee, van Duijnhoven, Corbett, Merrall, Cao, Panaccione, Panes, Steinwurz, Danese, Sands
This document will be available on October 26th 2025
Longer sustained remission in Crohn’s disease with guselkumab versus ustekinumab treatment: projections from a disease model
Dimova, Keng, Pan, Naessens, Salese, Yang, Kachroo, Gomez, Sanon
This document will be available on October 26th 2025
Maintenance of endoscopic and histologic improvements with guselkumab for ulcerative colitis at week 92 of the QUASAR long-term extension study
Hisamatsu, Panés, Magro, Lichtenstein, Allegretti, Bressler, Afif, Samaan, Duk Ye, Yarandi, Germinaro, Shipitofsky, Pandya, Miao, Zhang, Dignass, Rubin, Sands
This document will be available on October 26th 2025
Molecular differentiation of guselkumab and ustekinumab in moderately to severely active Crohn’s disease: post hoc analysis of the GALAXI 2 and 3 phase 3 studies
Richards, Sohn, Zeeman, Patel, McRae, Terry, Vetter, Reinisch, Cua, Branigan
This document will be available on October 26th 2025
Pharmacokinetics and exposure-response relationships of guselkumab intravenous or subcutaneous induction in participants with ulcerative colitis
Peyrin-Biroulet, Xu, Shao, Hisamatsu, Long, Danese, Germinaro, Vetter, Yarandi, Baker, Allegretti, Rubin
This document will be available on October 26th 2025
Symptom and quality of life benefits of achieving deep remission – a real-world study of patients with Crohn’s disease
Sanon, Knight, Meadows, Russnak, Wu, Kachroo
This document will be available on October 26th 2025
Symptom and quality of life benefits of achieving deep remission – a real-world study of patients with ulcerative colitis
Knight, Sanon, Meadows, Russnak, Wu, Kachroo
This document will be available on October 26th 2025
Treatment discontinuation in patients with inflammatory bowel disease (IBD) receiving biologic therapies that require intravenous (IV) infusions during induction and subcutaneous (SC) injections during maintenance: a claims-based study using data from two large US databases
Seminerio, Zhang, Uong, Adsul, Scapini, Busse, Dharia, Lu, Ungaro
This document will be available on October 26th 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
